Breast Cancer Medication - FOI Response Register

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

<5

• Abemaciclib + Fulvestrant
• Alpelisib + Fulvestrant
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
• Aromatase Inhibitor as a single agent
• Atezolizumab
• Capecitabine as a single agent
• Carboplatin + Paclitaxel
• Eribulin as a single agent or in combination
• Everolimus + Exemestane
• Fulvestrant as a single agent
• Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

<5

• Palbociclib + Fulvestrant

<5

• Parp Inhibitors (Olaparib/Talazoparib)
• Pembrolizumab
• Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
• Ribociclib + Fulvestrant
• Sacituzumab Govitecan
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 
• Transtuzumab deruxtecan

Trastuzumab as a single agent or in combination

<5

• Trastuzumab emtansine

 <5

• Any other active systemic anti-cancer therapy

<5

2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part

Nil – conducted via NHS Grampian

Where we have provided <5 answers this is because NHS Shetland considers that providing more specific information carries a high risk of identifying (or disclosing information about) individual patients. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.